Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine.
about
Targeting the epigenome in malignant pleural mesotheliomaDe novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome.De Novo Truncating Variants in ASXL2 Are Associated with a Unique and Recognizable Clinical Phenotype.Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer.Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.The Role of Additional Sex Combs-Like Proteins in Cancer.Novel compound heterozygous ASXL3 mutation causing Bainbridge-ropers like syndrome and primary IGF1 deficiency.Bainbridge-Ropers syndrome caused by loss-of-function variants in ASXL3: a recognizable condition.A de novo splice site mutation in EHMT1 resulting in Kleefstra syndrome with pharmacogenomics screening and behavior therapy for regressive behaviors.ASXL gain-of-function truncation mutants: defective and dysregulated forms of a natural ribosomal frameshifting product?ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1
P2860
Q33890546-467D7830-F542-4B4B-A5C2-6439D8BB8FEEQ36514637-AECA88FE-687F-4160-821D-2D5B16A78A91Q37342092-ED0B74FC-4DFC-4FC5-A2C5-FB0053DEB478Q37706554-A28D1A46-581B-439D-9CE5-ADDE09CA75A1Q38594002-E3C45EED-298C-461A-958E-7407DD37C467Q38928350-7E9CEE27-DA88-4D28-9F83-159E96B9D36FQ41263130-39315F3D-9314-4D1D-8804-185ED74E2DD9Q41921612-A8C9F9A5-38E0-46EE-8297-787EDD435DAAQ42293521-5ECB6A6C-31B2-4886-B02F-F03F14B2CEAFQ42689905-CCA21D24-A85B-4B75-A26D-322E61FA8D57Q47764443-602EA439-E48D-474A-8AE2-5E2B6C6AA454Q57804762-43E29A6E-E212-479A-8352-F98848E82072
P2860
Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Functional proteomics of the e ...... cs for translational medicine.
@ast
Functional proteomics of the e ...... cs for translational medicine.
@en
Functional proteomics of the e ...... cs for translational medicine.
@nl
type
label
Functional proteomics of the e ...... cs for translational medicine.
@ast
Functional proteomics of the e ...... cs for translational medicine.
@en
Functional proteomics of the e ...... cs for translational medicine.
@nl
prefLabel
Functional proteomics of the e ...... cs for translational medicine.
@ast
Functional proteomics of the e ...... cs for translational medicine.
@en
Functional proteomics of the e ...... cs for translational medicine.
@nl
P2860
P1476
Functional proteomics of the e ...... cs for translational medicine.
@en
P2093
Masaru Katoh
P2860
P304
P356
10.1586/14789450.2015.1033409
P577
2015-04-03T00:00:00Z